

2
3 **Status of selected ion flow tube mass spectrometry; accomplishments and**
4 **challenges in breath analysis and other areas.**

5 **David Smith^{†1} and Patrik Španěl^{1,2}**

6 ¹ Institute for Science and Technology in Medicine, School of Medicine, Keele University,
7 Thornburrow Drive, Hartshill, Stoke-on-Trent ST4 7QB, UK

8 ² J. Heyrovsky Institute of Physical Chemistry of Science, Academy of Science of the Czech
9 Republic, Dolejškova 3, 18223 Prague 8, Czech Republic

10 [†]Author for correspondence:

11
12 Tel.: +44 1782 674988

13
14 E-mail d.smith@keele.ac.uk

15
16 **Acknowledgements**

17 We acknowledge funding by The Czech Science Foundation GACR project 13-28882S.

18 **ABSTRACT**

19 This “Perspective” reflects our observations of recent accomplishments made using SIFT-
20 MS. Only brief descriptions are given of SIFT-MS as an analytical method and of the recent
21 extensions to the underpinning analytical ion chemistry required to realise more robust
22 analyses. The challenge of breath analysis is given special attention because, when achieved,
23 it renders analysis of other air media relatively straightforward. Brief overviews are given of
24 recent SIFT-MS breath analyses by leading research groups, noting the desirability of
25 detection and quantification of single volatile biomarkers rather than reliance on statistical
26 analyses, for breath analysis is to be accepted into clinical practice. A “SWOT” analysis of
27 SIFT-MS is made which should increase its utility for trace gas analysis.

28
29 **Keywords:** selected ion flow tube mass spectrometry, SIFT-MS, breath analysis, metabolites,
30 volatile organic compounds, small molecules, real time analysis, trace gas analysis, cystic
31 fibrosis, cancer, SWOT analysis.

Practitioners of selected ion flow tube mass spectrometry, SIFT-MS, have already eloquently described its unique strengths amongst the techniques available to gas phase analysis. So, in this “Perspectives” article we do not again describe the SIFT-MS technique in detail, but rather we simply briefly outline the physics and ion chemistry that underpin the technique in order to facilitate later criticisms, outline the major successes that differentiate it from other gas phase analytical techniques and then reveal the weaknesses of the technique and its shortcomings in analysis. An important aspect of this article will be to comment critically on recent endeavours to utilize SIFT-MS via its different modes of operation and to summarise results of some recent studies. We attempt to suggest more profitable directions for its future exploitation, especially when related to clinical diagnosis by breath analysis of specific diseases for which SIFT-MS has a special and possibly vital role to play. In this regard, direct breath analysis and the detection and quantification of volatile disease “biomarkers” is of special interest for reasons that were touched upon in our recent short perspective [1] and will be expanded in the present article using topical examples of the work from different research groups. We will also reveal our own in-train developments of the instrumentation that are designed to increase versatility and value for trace gas analysis of humid samples of air, exhaled breath and the headspace of biogenic fluids such as bacterial cell cultures, which we anticipate will increase its appeal and attraction to researchers in other topics in which real time trace gas analysis has an important contribution to make.

Selected ion flow tube mass spectrometry, SIFT-MS

■ Overview

The principle and operation of SIFT-MS has been given in several reviews [2-5]. It is sufficient to say here that it relies on the chemical ionization by selected reagent ions, H_3O^+ , NO^+ and O_2^+ , of trace analyte compounds in air/breath samples introduced at a controlled flow rate into a helium-buffered flow tube. Reactions occur between the selected reagent ion and the composite analyte molecules that produce characteristic product (analyte) ions that are identified and their currents (count rates) measured by a downstream analytical mass spectrometer/detection system. The identified analyte ions are related to specific neutral trace compounds in the air/breath from an in-depth knowledge of the ion-molecule chemistry and their count rates, coupled with physical parameters such as carrier (helium) gas and sample gas flow rates, and are converted to concentrations of the neutral trace analyte molecules in the sample [6]. A proper appreciation of the complex ion chemistry occurring in SIFT-MS reactors, especially when humid samples are being analysed, is critical to achieving accurate trace gas analysis and we comment on some perceived short comings in this aspect later in this article.

Two acquisition modes of reagent ion and analyte ion count rates are used, viz. the full scan mode, FSM, in which all ions within a chosen mass-to-charge ratio, m/z , are sampled and integrated over several scans, and the multiple ion monitoring mode, MIM, in which all the reagent ions and a few analyte ions are sampled and counted by rapidly switching the analytical mass spectrometer. Using MIM, greater precision of measurement can be realized and changing concentration time profiles of several trace metabolites in single breath exhalation to be obtained simultaneously [6, 7]. Currently, SIFT-MS instrumentation can achieve reliable quantification down to one part-per-billion by volume, ppbv, in one second

78 of analyte ion integration [8, 9]. Even sub-ppbv sensitivity has been claimed [10, 11],
79 typically using integration times in the order of minutes. Analyses of various media have
80 been carried out using SIFT-MS by us and others [12-18], not least of exhaled breath [19-24],
81 the results of which have been summarized in many research papers and some authoritative
82 reviews [2-4, 25-29]. We later critically appraise some of the more recently reported studies.

83
84 The extension of the SIFT-MS data acquisition approach was made possible by software
85 developments that allow the count rates of all reagent and analyte ions to be determined at
86 integer m/z values across the full mass spectral scan range available using the MIM approach.
87 The m/z range accessible in the current *Profile 3* instruments is up to 300. This allows
88 statistical assessment of the mass spectral data and thus a careful critique of the use and
89 misuse of the PCA approach to the identification of diagnostic biomarkers.

91 ■ Ion chemistry

92 As has been pointed out, SIFT-MS analysis depends on chemical ionisation using (precursor)
93 reagent ions, H_3O^+ , NO^+ or O_2^+ , to generate the characteristic product (analyte) ions of the
94 trace molecules in the sample being analysed [4]. The resulting analytical spectra are much
95 simpler and more easily interpreted than those obtained using electron ionisation to analyse
96 complex media like exhaled breath. Thus, m/z overlaps of analyte ions are fewer allowing
97 trace compounds in air/breath samples to be unambiguously analysed more rapidly than when
98 using pre-concentration and separation techniques in association with gas
99 chromatography/mass spectrometry (GC-MS). This precious feature of SIFT-MS facilitates
100 real-time trace gas analysis, including the analysis of single breath exhalations in real time, as
101 discussed later.

102 However, there is a sting in the tail! It is essential that the complex ion chemistry taking place
103 in the flow tube that is the ion chemistry reactor be thoroughly understood and proper ion-
104 molecule kinetics data obtained to achieve accurate trace gas analyses. Such knowledge is not
105 easily acquired; it has needed decades of research work by the authors to have gained
106 sufficient understanding to conceive of and implement SIFT-MS as the reliable analytical
107 technique it has become. Even under the truly thermalized conditions of SIFT-MS, the ion
108 chemistry can be rich and several reaction mechanisms may occur that have to be understood
109 in order to interpret the analytical mass spectra. Complications are minimised by the use of
110 helium carrier gas, because it is relatively inert chemically, but even helium atoms are
111 intimately involved in some of the ionic reactions, especially those involving the formation of
112 adduct ions, as mentioned below.

113
114 The reactions of the three available reagent ions are very different and each must be
115 understood if these reactions are to be used for analysis. H_3O^+ ions react with most
116 molecules, M , including volatile organic compounds (VOCs), by the process of proton
117 transfer resulting in MH^+ ions, but it is important to realise that for many organic molecules
118 spontaneous dissociation of the nascent $(\text{MH}^+)^*$ ions can occur, often with the ejection of an
119 H_2O molecule. Obviously, if this is not appreciated then gas analysis will be inaccurate and
120 even meaningless. The analogous ion chemistry underpinning the PTR-MS drift tube is more
121 complicated [8], given that both the reagent and analyte ions are suprathreshold (kinetically
122 excited) promoting break-up of the analyte ions in collisions with heavy nitrogen and oxygen
123 carrier gas molecules rather than lighter helium carrier gas atoms used in SIFT-MS. We
124 discuss this phenomenon later in relation to our recent development of our SIFDT-MS. NO^+
125 ions react with VOCs by several defined mechanisms, including charge transfer producing
126 M^+ ions, hydride ion transfer producing $(M\text{-H})^+$ ions and by ion-molecule association

127 producing NO^+M adduct ions. $\text{O}_2^{+\bullet}$ ions react by charge transfer with most molecules, which
128 with small molecules like NH_3 and NO is non-dissociative producing the parent radical cation
129 (e.g. NH_3^+ and NO^+). However, $\text{O}_2^{+\bullet}$ reacts with most VOCs producing two or more fragment
130 ions, and this minimises its value as a SIFT-MS reagent ion. This critical ion chemistry
131 knowledge has been acquired by many studies of the reactions of these three reagent ions
132 with groups and homologous series of many biogenic VOCs, [5, 30-32] in order to build the
133 kinetics library needed for SIFT-MS analyses. [6, 9]
134 Detailed discussion of the relevant ion chemistry is given in the cited references. But it is
135 vital now to discuss two aspects of it that are often not appreciated by those who attempt to
136 advance SIFT-MS by increasing analytical sensitivity and to extend its application. These
137 related to the analysis of very humid samples such as exhaled breath and the use of carrier
138 gas other than inert helium, especially nitrogen. Inevitably, especially when exploiting H_3O^+
139 and NO^+ reagent ions for analysis, hydrated ions of both the reagent ion efficiently form, viz.
140 $\text{H}_3\text{O}^+(\text{H}_2\text{O})_{1,2,3}$ and $\text{NO}^+(\text{H}_2\text{O})_{1,2}$, and the analyte ions, viz. $\text{MH}^+(\text{H}_2\text{O})_{1,2,3}$ and $(\text{M}-$
141 $\text{H})^+(\text{H}_2\text{O})_{1,2}$. The hydrated reagent ions must be considered as additional reagent ions in the
142 analysis and this is not a trivial task, because these cluster ions are continuously formed along
143 the length of the flow tube and so the reaction times of these additional reagent ions have to
144 be estimated. We have addressed these complicating aspects of SIFT-MS analysis in detail,
145 and constructed appropriate analytical expressions that involve the rates of these hydration
146 processes [6, 32, 33]. This would not have been possible without a detailed understanding of
147 the ion hydration process we have acquired by many experimental investigations [30, 31].
148 Thus, trace gas analysis can now be achieved to acceptable accuracy in very humid samples,
149 as we have demonstrated in several papers [9, 18, 28, 34, 35].
150 A closely related phenomenon is the formation of weakly-bound adducts by the association
151 of the reagent ions with the other abundant molecules of the sample gas i.e. N_2 , O_2 and, in
152 exhaled breath, CO_2 . Thus, adduct ions such as $\text{H}_3\text{O}^+\text{N}_2$, $\text{H}_3\text{O}^+\text{CO}_2$, NO^+CO_2 , $\text{O}_2^{+\bullet}\text{O}_2$ and
153 $\text{O}_2^{+\bullet}\text{CO}_2$ can clearly be detected in a mixture of the helium carrier gas and dry air. The danger
154 is that these adduct ions may be isobaric with an analyte ion formed in the analysis of some
155 common trace compounds in biogenic mixtures and then quantification can be compromised.
156 For example, $\text{H}_3\text{O}^+\text{N}_2$ ions are isobaric with protonated ethanol (m/z 47) and $\text{H}_3\text{O}^+\text{CO}_2$ is
157 isobaric with the monohydrate of protonated acetaldehyde (m/z 63). Whilst these two adduct
158 ion species are very reactive, especially with H_2O molecules, they are formed in the analysis
159 of humid exhaled breath and must be accounted for to achieve accurate analyses. [36].
160 Similarly, the formation of $\text{O}_2^{+\bullet}\text{CO}_2$ (m/z 76) when using $\text{O}_2^{+\bullet}$ reagent ions to analyse CS_2 in
161 exhaled breath is a real problem (analyte ion in this case is CS_2^+) [37]. The formation of
162 $\text{H}_3\text{O}^+\text{N}_2$ will be particularly efficient when using nitrogen carrier gas that has been used in
163 recent SIFT-MS analyses [38] or air as it is routinely used in PTR-MS [39, 40]. An essential
164 point to make is that even though these adduct ions are not immediately detected by the
165 downstream analytical mass spectrometer system, they are surely formed and undergo
166 reactive loss especially with H_2O molecules and other VOCs. These complications are
167 generally not understood by most SIFT-MS and PTR-MS users and so for accurate analyses
168 they must rely on calibration of their instrument using standard mixtures. But there are even
169 dangers in this approach unless the calibrations are carried out at calibrant gas concentrations
170 that are close to the concentrations in the sample mixtures to be analysed. It is our contention
171 that over reliance on such calibrations without a good understanding of the analytical ion
172 chemistry can lead to unrecognised inaccuracies. This is especially so when wide variations
173 in trace gas (metabolite) concentrations occur in humid air/breath samples and when
174 opportunistic variations in reactor conditions such as sample flow rate and variable E/N in
175 PTR-MS are exploited ostensibly to improve analyses.

176
177
178
179
180
181

Finally, it is important to recognise that all users of SIFT-MS will not have a thorough background in ion chemistry and cannot be expected to appreciate all these nuances. However, to introduce a new compound into the analytical kinetics library requires an appreciation of this ion chemistry and thus will usually need the input of experts in the field.

182 ■ **Breath analysis**


183 SIFT-MS is now used to analyse air samples for trace VOCs in several areas of research, as
184 listed in our recent reviews [2-4, 25-29]. However, it is in breath analysis where the real
185 analytical challenges are revealed, because exhaled breath is supersaturated with water
186 vapour, which most analytical techniques are not able to cope with when de-humidification is
187 often required that can partially, which can partially or totally remove some trace compounds
188 from the breath sample. But SIFT-MS not only copes with the high humidity but actually
189 measures the humidity providing a very valuable method to check sample humidity (water
190 vapour content), which for exhaled breath is always close to 6% by volume, and of sampling
191 integrity [9, 41]. Thus, breath analysis is directed towards identifying abnormal
192 concentrations of VOC metabolites, distinguishing endogenous from exogenous compounds
193 and to detect, identify and quantify biomarker VOCs related to disease. Given that the
194 concentrations of most volatile biomarkers in exhaled breath are low, often at parts-per-
195 billion by volume, ppbv, or lower, this is a real challenge that the analytical instrumentation
196 must meet and provide sufficiently accurate and precise to be useful clinically. If this can be
197 performed directly both in real time and on-line avoiding sample collection that and provide
198 immediate analytical results, then the most reliable breath analyses can be obtained. Such is
199 the promise of SIFT-MS, as is shown below by sample data.

200 Unfortunately, so much breath analysis research is focused on efforts to simply identify
201 volatile compounds of particular disease states by comparing the composition of breath from
202 “healthy” subjects with breath from patients with particular disease states, paying too little
203 attention to quantification that is essential to establish meaningful biomarkers. It is stating the
204 obvious that it is of little value to inform a person that they have cholesterol in their blood
205 without giving its concentration; the same should apply to breath biomarkers! Too often,
206 most workers are apparently satisfied to reveal groups of breath biomarker compounds by
207 statistical analysis of trace compound data derived from healthy/diseased groups of
208 volunteers, rarely attempting to identify and quantify individual compounds. Such data are
209 interesting and can be a guide to further research, but they are of little value to clinicians and
210 are quickly archived. It is our contention that much more effort should be given to the
211 identification and quantification of discrete breath biomarkers; in this we have had some
212 success, as outlined later. It would be remiss not to mention that breath analysis is indeed
213 used to effect in monitoring asthma via breath nitric oxide levels [42, 43] and in monitoring
214 exhaled breath $^{13}\text{CO}_2$ following the ingestion of ^{13}C -labelled compounds to pinpoint and track
215 specific metabolic disorders and diseases [44, 45]. Otherwise, the clinical return for the recent
216 rapid increase in breath analysis research has so far been small, principally due to poorly
217 directed research, some examples of which we describe in this article.

218 But it is not our intention in this “Perspective” to diminish the contribution of other users of
219 SIFT-MS in their efforts to progress breath analysis and especially those involved in the
220 search for biomarkers that could make an important contribution to clinical diagnosis and
221 therapy monitoring. Rather, it is to steer the work towards a more rapid and clinically
222 profitable approach to the desirable objectives that we all passionately desire. As mentioned
223 above, we concentrate on breath analysis but not exclusively, because SIFT-MS is being
224 profitably used in other areas, notably environmental (air pollution) monitoring and food

225 flavour research that will briefly be referred to later and for which small instrumental
226 development is also very desirable.


227
228 Breath sampling and analysis is essentially a simple, non-invasive and painless procedure that
229 can be accomplished easily even by babies and frail patients. Sample collection by exhalation
230 into bags followed by off-line analysis has been most commonly used, which inevitably
231 provides a mixture of breath from the alveoli and the respiratory airways. Attempts have been
232 made to selectively collect end-tidal breath (sometimes inaccurately termed alveolar breath)
233 using exhaled carbon dioxide monitoring. This may be worthwhile ultimately, but at the
234 expense of more complex, less direct sampling procedures that can compromise the breath
235 sample due to condensation and cross contamination from additional tubing and circuitry. So
236 we doubt that such efforts are really useful at the current stage of breath research, since they
237 deflect from the much more challenging analytical issues involved in the search for real
238 biomarkers. It is suggested by some that this sampling approach can minimise contamination
239 of the mouth-exhaled breath sample by compounds generated in the oral cavity. This is
240 pertinent, but it does not stand thorough examination since the exhaled breath still passes
241 through the mouth. Yet it is true that mouth generation is not taken sufficiently serious in
242 breath sampling and mostly is deliberately ignored. Surely, a better approach is to bypass the
243 oral cavity by sampling breath exhaled via the nose? Of course, this presents an additional
244 practical problem to breath sampling, and whilst not necessarily providing a true breath
245 composition related to alveolar and airways origin only, it is a close approximation. We
246 further address this situation below in relation to real time breath analysis that obviates breath
247 sample collection and off-line analysis.



248
249 **Fig. 1** A schematic diagram of the *Profile 3* SIFT-MS instrument indicating the major functional parts.
250 Decreasing ion currents pass sequentially through the three orifices indicated. Both direct breath sampling and
251 sampling from ambient air or liquid headspace are depicted. Reproduced from [4] with permission from RSC.

252

253 Breath analysis in real time by SIFT-MS is achieved by displacing the ambient air from the
254 entrance to the heated calibrated capillary with directly-exhaled breath (see Figure 1) whilst
255 running the detection mass spectrometer in either the FS or the MIM mode. The sampling
256 entry lines are held at around 70 C to inhibit surface adsorption of water vapour and
257 condensable compounds. A disposable mouthpiece is used for mouth sampling of exhaled
258 breath; inhalation through the mouth re-establishes ambient air at the capillary entrance for
259 analysis. Several mouth exhalation/inhalation cycles are analysed for breath-by-breath
260 consistency checks. Alternatively, breath sample collection into vessels for off-line analysis
261 can be used, but water-soluble compounds such as ammonia can readily adsorb onto the
262 vessel surfaces and thus distort the analysis. Bacterial filters must be used for on-line breath
263 sampling from patients with infectious respiratory diseases. Typical data obtained for direct
264 on-line breath sampling by SIFT-MS are shown in Figure 2 showing the well-defined
265 exhalation time profiles and the derived concentrations of the several compounds that range
266 from percentage levels (water vapour and carbon dioxide) to the ppbv levels of two trace
267 metabolites (hydrogen cyanide and acetone) that carry the physiological and clinical data.



268
269 **Fig. 2** Time concentration profiles for water vapour and CO₂ (in %) and acetone and HCN (in parts-per-billion
270 by volume, ppb) for six sequential breath exhalations obtained using the MIM mode of the *Profile 3* SIFT-MS
271 instrument, indicating the remarkable breath-to-breath consistency in the derived concentrations of all four
272 compounds. Also, indicated to the right, are the laboratory air concentrations of each compound. Reproduced
273 from [4], with permission from RSC.

274

276 What is so satisfying is that this sampling procedure can be easily modified to sample breath
277 exhaled via the nose. Thus, a small vacuum pump is included in the SIFT-MS sampling line
278 downstream in order to draw ambient air or exhaled breath across the entrance to the
279 sampling capillary. The flow rate of air/breath must be adjusted to be much smaller than
280 breath exhalation rates via the mouth or the nose to ensure that normal breath exhalations
281 from the mouth and from the nose are not compromised. Then sampling of the exhaled breath
282 from one nostril for about 10 s with both the second nostril and the mouth closed provides an
283 on-line analysis of nose-exhaled breath. Closing both nostrils and sampling from the mouth
284 indicates which compounds are predominantly produced in the oral cavity. Thus, analyses of
285 specific selected compounds present in mouth-exhaled breath, nose-exhaled breath and
286 mouth cavity air can be performed sequentially in real time in less than a minute. Such
287 studies have provided very interesting data that show which compounds are predominantly
288 produced in the oral cavity and those that are largely systemic. For example, ammonia and
289 ethanol mostly originate in the oral cavity (influenced by oral hygiene) and acetone and
290 isoprene are entirely systemic in origin. It is now apparent that much of the analyses carried
291 out on mouth-exhaled breath are surely contaminated by orally-generated compounds and
292 future studies must address this point. We have also demonstrated that collection of nose-
293 exhaled breath can be performed using a pump in the nose sampling line to inflate flexible
294 bags, but it has to be appreciated that this can take a few minutes and so during the inhalation
295 phase of breathing the sampled air will be diluted with laboratory air. This can be accounted
296 for by normalising to the breath acetone level as measured directly in mouth exhalations and
297 the laboratory air composition as measured during inhalations, according to the simple SIFT-
298 MS protocol outlined above. We have trialled this sampling procedure even by analysing the
299 nose-exhaled breath of small babies with some success.

300

301


302 **Recent SIFT-MS studies: review and assessment**

303 The exploitation of SIFT-MS for trace gas analysis is growing in a number of fields and is
304 limited currently mostly by the availability of affordable instrumentation. This undesirable
305 situation needs to be rectified and we indicate the possible solution to this towards the end of
306 this article. Even so, some hundreds of research papers have been published with SIFT-MS
307 analyses as their focus and some reviews have been published that are a quick source of
308 summary information [2-4, 25-29]. Unfortunately, some papers are uncritical and propagate
309 some of the least desirable and unproductive approaches to SIFT-MS analyses. However, the
310 results of much careful and thorough work have been reported notably by the groups of R.
311 Dweik, C. Turner, B. Ross, G. Hanna in addition to our own contributions at Prague and
312 Keele. But it must be said that the approaches of all these groups have their strengths and
313 weaknesses; by critical appraisal, ways are variously suggested to better exploit SIFT-MS for
314 trace gas analysis. We now briefly review and assess some of these studies that are largely
315 directed towards disease detection, after which we address SIFT-MS through a SWOT
316 analysis that, we hope, faithfully represents the current standing of SIFT-MS as a gas phase
317 analytical method.

318 **▪ Ion chemistry: additional data**

319 To begin, it is appropriate to again recognise the requirement of a proper understanding of the
 320 ion chemistry that occurs in the SIFT-MS reactor to realise reliable analyses of humid air. If
 321 there is a general criticism of SIFT-MS work in most laboratories it is that not enough
 322 thought is given to this ion chemistry and proper quantification of trace compounds, which
 323 can be disastrous in medical studies. So it is desirable, even essential, to confirm the nature of
 324 assumed analytic ions of specific compounds formed under the specific conditions of the
 325 particular SIFT-MS instrument by the use of their pure compounds to confirmed the ion
 326 chemistry involved. Whilst this requires more work, it is more likely to produce reliable
 327 results. We also take the view that to be certain of compound identification, parallel GC-MS
 328 measurements should be carried out which, whilst not totally fool proof, can increase
 329 confidence in compound identification. It also makes good sense to attempt to trace the likely
 330 biochemistry forming breath biomarkers. Too little attention is given to these difficult aspects
 331 and the risk is that erroneous compound identification may take place.

332 Relevant ion chemistry studies continue to be reported, which can be of great help to SIFT-
 333 MS practitioners. A good example is the recent work of Amelynck and his group [46, 47] in
 334 which great efforts have been made to identify isomeric forms of terpenoid aldehydes,
 335 highlighting the fact that many biogenic trace compounds have several structural isomers that
 336 ideally should be characterised in analysis. Similar comments apply to isobaric compounds
 337 that are often difficult to separate in SIFT-MS, but this problem can be alleviated by using
 338 both H_3O^+ and NO^+ , and perhaps O_2^+ , reagent ions to analyse the sample, exemplified by a
 339 detailed study of the reactions of seven hexanol isomers [31]. Non-isomeric yet isobaric ions
 340 can also be separated with careful thinking, this being illustrated by the quantification of
 341 acetaldehyde, dimethyl sulphide and carbon dioxide involving isobaric analyte ions [48]. A
 342 recent, exciting study involves the study of the ion chemistry of malondialdehyde (MDA, see
 343 Figure 3) that has been proposed to reflect free oxygen-radical lipid peroxidation. This has
 344 allowed a kinetic library entry to be constructed for MDA in SIFT-MS which allows, for the
 345 first time, the detection of gaseous MDA as generated by *in vitro* cell cultures [18]. This
 346 study illustrates the effort that is often required to extend SIFT-MS analysis to biogenic
 347 compounds, which include many carboxylic acids for which the kinetics database entries
 348 have recently been constructed [32].




349
 350 **Fig 3.** A full scan mass spectrum obtained when the headspace of freshly synthesised malondialdehyde (MW
 351 72) water solution was analysed by SIFT-MS using NO^+ reagent ions showing four characteristic product ions at
 352 m/z 71, 89, 102, 120; see text for further explanation. Reproduced from [18] with permission from Wiley.

354 ■ Volatile metabolites in exhaled breath and released by cell cultures

355 Many SIFT-MS studies have been directed towards the detection in exhaled breath of volatile
 356 metabolites related to particular disease states. Notable contributions have been made by the
 357 aforementioned groups. Our approach to this potentially valuable disease diagnostic support
 358 has been to focus largely on the search for single compound breath biomarkers and with some
 359 success, as we review later. However, single volatile metabolite biomarkers of disease are
 360 considered by most workers in the field to be unlikely but why, given that there are numerous
 361 non-volatile blood single biomarkers routinely used for diagnosis? Hence, most breath
 362 researchers take a more pragmatic approach which is to identify groups of compounds that
 363 differentiate the composition of breath from patients with particular diseases from the breath
 364 of healthy controls.

365 Very active amongst the groups exploiting SIFT-MS is that of Raed Dweik at Cleveland,
 366 USA who, in this way, has made a valiant effort to demonstrate the value of breath analysis
 367 by several pointed studies, including the analysis of breath **volatile metabolites** as a non-
 368 invasive tool to diagnose chronic liver disease [49], non-alcoholic fatty liver disease in
 369 children [50], identifying unique “breathprint” in patients with inflammatory bowel disease
 370 (IBD) [51] and acute decompensated heart failure [52], “breathprints” in children with IBD
 371 [53] (see Figure 4) for obese children compared to lean children as controls [54, 55], children
 372 with juvenile idiopathic arthritis [56] and studies of breath **volatile metabolites** in patients
 373 with pouch disorders [57].



374 **Fig. 4.** Typical results of a SIFT-MS study aimed at discovery of combinations of VOCs discriminating between
 375 IBD patients and healthy controls [53]. (a) Visualisation of linear canonical discriminant analysis demonstrating
 376 that 21 pre-selected VOCs can classify patients with IBD or as healthy controls. (b) Receiver operating
 377 characteristic (ROC) curve analysis, demonstrating accuracy of predicting the presence of IBD by 1-octene, (E)-
 378 2-nonene and 1-decene taken separately and in a linear model combination that gave the best area under the
 379 curve (AUC) of 0.96. Reproduced from [53] with permission from Wiley.


381 Differentiation between healthy and patient groups relies heavily on statistical analyses and
 382 often involves the measured concentrations of common and abundant breath compounds such
 383 as ammonia, acetone and isoprene that generally have a wide biological variability, even in
 384 the exhaled breath of healthy people, therefore having questionable validity. These analyses

385 also often include rarer low concentration compounds that are sometimes difficult to
386 definitely identify and quantify by SIFT-MS alone, especially when the ion chemistry
387 complications in SIFT-MS analyses of humid breath described in the previous section are not
388 fully appreciated. This is why we consider that parallel GC-MS (with pre-concentration
389 techniques) are needed to support identification and quantification of low-level new
390 compounds in exhaled breath. Whilst the derived results of this substantial body of research
391 are thought-provoking, can they be more than just a prelude and a guide to further work and
392 what is their value clinically at this early stage? Even the most carefully thought-out
393 statistical analyses can lead to ambiguous and doubtful results, as we show later. A final
394 comment relates to the use of the term “breathprint” for mass spectral patterns. If this is
395 intended to be analogous with “fingerprint” it is misplaced, since in breath analysis use only a
396 pattern is described and not the depth of the impression. It must be appreciated that for
397 meaningful breath analysis in medicine the concentrations of the various biomarkers must be
398 accurately measured.

399 Similar wide-ranging research is being carried out by the group of George Hanna at Imperial
400 College London, UK, currently with a sharp focus on the detection and quantification of
401 biomarkers in the breath (and urine) of oesophageal-gastric (OG) cancer patients, their
402 surgical speciality. In a series of paper involving SIFT-MS analyses of exhaled breath and the
403 headspace of gastric fluid and urine [20, 22, 58-61], they have searched for volatile
404 biomarkers of OG cancer, anticipating that such could greatly help the early diagnosis and
405 follow-up therapy after surgery. SPME/GC-MS and ATD/GC-MS have been added to their
406 analytical armoury to firm up trace compound identification. [1]. Again, heavy reliance is
407 placed on statistical analysis to differentiate component VOCs of patient samples and
408 controls, including the use of optimisation of ROC curves to achieve diagnostic accuracy. Yet
409 these ROC curves were constructed from the concentrations of several VOCs in combination,
410 a questionable procedure that we consider later with respect to SIFT-MS data on breath
411 analysis obtained in our Prague laboratory. An interesting and potentially important aspect of
412 their investigations is the involvement of higher-order aldehydes (C3-C10) in tumour
413 biogenesis, research that combines aldehyde detection and genetic manipulation of tumour
414 cells concurrent with investigations of C3-C10 aldehydes in the exhaled breath of healthy
415 subjects [62] This clever work holds real promise and signals a more imaginative approach
416 to breath gas analysis by searching for the biochemical origins of the aldehydes. The
417 pioneering work of this group in direct sampling of exhaled breath in the perioperative setting
418 well demonstrates the real time analyses that are possible by SIFT-MS [7]. Recently, they
419 have extended their research to the analysis of the exhaled breath of patients suffering from
420 inflammatory bowel disease [63].

421 Claire Turner, formerly at the Silsoe Research Institute (SRI) and currently at the Open
422 University, UK, is one of the original users of SIFT-MS for breath analysis [64-68]. The
423 work of her research team has been varied and combines both the search for breath
424 biomarkers using multivariate statistical methods and also the investigation of single
425 biomarkers, notably acetone and its association with diabetes [69], which has realised some
426 interesting results. The work of the group is notable in that it exploits several analytical
427 methods and compares the data obtained from specific studies, exemplified by the use of GC-
428 MS, HPLC-MS and SIFT-MS in conjunction with multivariate classification for the diagnosis
429 of Crohn’s disease by urine analysis [70]. Recent work involves the development and use of
430 portable breath sensor devices for monitoring diabetes and their quantitative validation using
431 SIFT-MS [71], the analysis of the volatile faecal metabolome for screening of colorectal

432 cancer that showed hydrogen sulphide, dimethyl sulphide and dimethyl disulphide were
433 apparently elevated in patients at high risk of colorectal cancer [72], and the analysis of



434

435 **Fig. 5.** Typical results of a SIFT-MS study aimed at discovery of single volatile metabolites in faecal
436 metabolome as biomarkers of colorectal cancer [72]. (a) Results of SIFT-MS analyses of faecal headspace
437 collected from low risk and high risk colorectal cancer groups obtained using H_3O^+ reagent ions and the count
438 rate of the analyte ion at m/z 35 (protonated hydrogen sulphide) (b) corresponding results for count rate at m/z
439 90 (presumably a protonated nitrogen containing molecule). Reproduced from [72] under the Creative
440 Commons Attribution.

441 VOCs faecal samples from rats fed control diets [73].


442 The work of the group of Brian Ross in Ontario, Canada, another pioneer of SIFT-MS, takes
443 the eye being the first to combine sample concentration techniques (TD) with real time SIFT-
444 MS analysis to improve detection sensitivity [10, 74, 75]. The group has also recognised the
445 importance of nose-exhaled breath analysis, as emphasized in the previous section, and
446 combined TD and SIFT-MS to analyse nose-exhaled and mouth-exhaled breath showing that
447 mouth-exhaled hydrogen sulphide [76], a known neuromodulator or cofactor, is largely
448 generated in the oral cavity [77]. This work is truly exploiting the strength of SIFT-MS and
449 shows one of its real advantages in breath analysis research. They also carried out the first
450 meaningful studies of aldehydes as biomarkers of lipid peroxidation [78] and the release of
451 these compounds from brain and liver cells following dietary supplementation with n-3
452 polyunsaturated fatty acids [79]. Their work has even reached towards food science [80] and
453 plant and fungal science with the quantification of methanol both chemically and biologically
454 generated from lignin [81].

455 SIFT-MS was conceived and developed at Keele by the authors subsequently with a major
456 contribution to its development in Prague. During its continuous development as a research
457 and commercial analytical tool it has been used in the manner original intended, which is as a
458 real-time analytical technique that can uniquely contribute to the methods now available for
459 trace gas analysis of ambient air and exhaled breath. Its development and much of the
460 research work carried out by its exploitation up to 2011 by us and others are summarised in
461 two major review papers [3, 5] and subsequent work is reviewed in more recent papers [26,
462 28]. In relation to breath analysis, a major contribution has been the provision of
463 concentration reference ranges of common breath metabolites, in close collaboration with the
464 aforementioned Claire Turner [64]. These were constructed by direct on-line, real-time SIFT-

465 MS analyses (obviating sample collection) of the exhaled breath of the healthy population. As
466 far as disease detection is concerned, we have tried to focus on the detection and
467 quantification of single breath biomarker compounds of specific diseases that, we believe, are
468 most desirable, since they would be more readily utilized for clinical diagnosis and
469 therapeutic monitoring. In this pursuit we have had some success, as summarised by the
470 following:

- 471 • Serendipitous detection of gaseous **hydrogen cyanide** (HCN) when analysing by
472 SIFT-MS the volatile emissions from cultures of *Pseudomonas aeruginosa* (PA)
473 bacteria derived from patients with cystic fibrosis (CF), initiated a decade of research
474 at Keele and Prague on the presence of HCN in the headspace of *in vitro* cultures of
475 different strains of PA and in the exhaled breath of patients with CF. This has
476 established HCN as a reliable single and discrete biomarker of PA infection of the
477 airways and lungs [29, 82-86].
- 478 • During this SIFT-MS PA/HCN research it was noticed that **methyl thiocyanate** was
479 also emitted by PA cultures, its positive identification being confirmed by the analysis
480 of the culture headspace with SPME/GC-MS following which SIFT-MS was used to
481 quantify this VOC. [87, 88]. This was the first demonstration of the parallel use of
482 SIFT-MS and GC-MS for trace gas analysis, a procedure that we now adopt routinely
483 in the analysis of biogenic media and which we strongly encourage others to adopt.
- 484 • Detailed studies of exhaled breath of patients with Crohn's disease (CD) and
485 ulcerative colitis (UC) have revealed elevated levels of **n-pentane** relative to healthy
486 controls [89, 90]. This required a detailed challenging study of the ion chemistry
487 involved in n-pentane detection and quantification by SIFT-MS and which now
488 allows this hydrocarbon to be detected in very humid breath, which can ultimately
489 assist the non-invasive screening of inflammatory processes such as CD and UC.
- 490 • During a collaborative study with clinicians focused on the composition of exhaled
491 breath from those suffering from gastroesophageal reflux disease (GERD), it was
492 discovered that the only VOC elevated in their breath relative to controls was **acetic**
493 **acid**. Again, both SIFT-MS and GC-MS were exploited for this study. This indicates
494 that breath acetic acid may be a useful indicator of GERD and other conditions that
495 result in a lowering of pH of the lining of the airways [21]. It is exciting to note that in
496 a very recent study (as yet unpublished), acetic acid is observed to be greatly elevated
497 in the exhaled breath of cystic fibrosis patients, which may have important
498 implications to the treatment of this disease.
- 499 • **Methane** is present in the exhaled breath of all human beings and, along with
500 hydrogen, when elevated it is a reflection of gut bacterial overload. We have
501 developed SIFT-MS to quantify breath methane on-line in single breath exhalations
502 using the slow reaction of $O_2^{+•}$ reagent ions with methane [91]. Based on this work,
503 breath methane concentration profiles have been constructed during exercise on an
504 ergometer using the analogous PTR-MS real time analytical method [92], ostensibly
505 providing a detector of gut bacterial overload.
- 506 • As the expected new innovators of SIFT-MS-type instrumentation, we must not
507 remain complacent. Thus, thoughts are continuously directed to improving compound
508 identification and analytical sensitivity. For the former, we consider the idea of
509 introducing TOF-MS higher resolution analysis to differentiate isobaric ions, but this
510 would not be a panacea [8] and would greatly increase the cost of instrumentation. To

511 increase analytical sensitivity, new approaches to the thermal desorption of volatile
 512 compounds extracted from breath by sorbent tubes and its direct link to SIFT-MS are
 513 under development in Prague. Whilst acknowledging that the precious real-time direct
 514 analysis of exhaled breath and biogenic fluid headspace will be compromised, we
 515 believe that this will ultimately improve accuracy of quantification and simplify
 516 remote breath sample collection, transport and storage. Further to these developments,
 517 we have commenced research in the area of selected ion flow drift tube mass
 518 spectrometry, SIFDFT-MS, which has some distinct advantages over SIFT-MS due to
 519 the inclusion of a low intensity drift field in the analytical reactor whilst retaining all
 520 the features of rapid analysis and immediate quantification [93, 94] (see Figure 6).




521
 522 **Fig. 6.** Schematic drawing of the selected ion flow-drift tube, SIFDFT, apparatus recently developed in Prague. In
 523 this representation the sample gas introduction setup is represented by a glass vial containing 10 mL of liquid
 524 water through which dry synthetic air or laboratory air is introduced but direct or bag samples of breath can be
 525 readily introduced. Note that the speed of the helium carrier gas is reduced by a restrictive aperture between the
 526 flow-drift tube compartment and a scroll pump in this case. Reproduced from [94] with permission from ACS.

527 The New Zealand groups (Malina Storer; Michael Epton) have made various contributions to
 528 breath research using the commercial SIFT-MS instruments *Voice 100* and *200* (Syft
 529 Technologies, New Zealand), including both off-line and on-line measurement of exhaled
 530 HCN in relation to PA infection [95, 96], acetone in relation to diabetes [97] and critical
 531 illness [98]. They have also carried out breath testing in the workplace, particularly for
 532 acetonitrile exposure, the persuasive results of which are shown in Figure 7 [99]. A final
 533 development of note by Syft Technologies is the use of a SIFT-MS device *Voice 200* loaded
 534 on a mobile van, which has been used for monitoring ambient air and exhaled breath for
 535 aromatic hydrocarbons to assess exposure to these compounds [100].

536

537
538



539

540 **Fig. 7.** Acetonitrile concentration measured by SIFT-MS in the exhaled breath of people who spent time
541 working in a chemistry department laboratory where acetonitrile was used as a solvent. Reproduced with
542 permission from IOP from [99].

543 Some achievements using SIFT-MS in other areas

544 The various areas in which SIFT-MS analysis is exploited are tabulated and reprised in a
545 recent review [26] so they need not be discussed in detail here. However, in addition to breath
546 research, worthy of mention is the significant work carried out in analysing VOCs from food
547 flavours and processed food, largely by Sheryl Barringer in Ohio, USA [15, 101-104] and M
548 Monica Flores in Valencia, Spain [105, 106]. Interesting work has also been done on the
549 deodorization of breath following the ingestion of raw garlic by various food and food
550 components, essentially to remove the odorous organosulphur compounds. It was observed
551 that the enzymatic activity, of polyphenolic compounds and the acidity of specific foods may
552 cause a reduction of these volatiles, but chlorophyll does not cause a deodorization effect.
553 [107]

554 Studies of VOCs emitted by mammalian and bacterial cell cultures have been carried out in
555 several laboratories following the early work [108-112], but it would neither do justice nor
556 be appropriate to summarise these detailed programmes here; rather, the reader is referred to
557 recent papers on the subject [12, 108, 113-117]. But it is important to state that SIFT-MS real
558 time analysis of the VOC emissions, including real time measurements during the evolution
559 of bacterial cultures [118, 119], is ideal for these studies since it avoids sample collection and
560 can be carried out over long (incubation) time periods.

561
562

563 The strengths, weaknesses, opportunities and threats

564 The *strengths, weaknesses, opportunities* and *threats* (SWOT) of and to SIFT-MS are worth
565 analysing as we perceive them.

566 The **strengths** of SIFT-MS are articulated throughout this article. It is a powerful method for
567 real-time breath analysis, ambient air analysis and the analysis of cell cultures headspace. It is
568 an analytical method that uniquely can accurately and reliably measure concentrations of
569 identified biomarkers of diseases in exhaled breath. To be useful clinically, such
570 measurements must be objective and reproducible in all laboratories and clinics throughout
571 the world, a requirement that analytical methods such as SPME/GC-MS can rarely fulfil
572 without tedious and careful calibration. This is vital and important if reference ranges of

573 breath metabolites are to be established in the same sense that are other crucial biomarkers
574 such as blood pressure and cholesterol levels are accepted for health monitoring and control.
575 The *weaknesses* of SIFT-MS relate to the limit of quantification, the practical lower limit
576 being at about 1 ppbv in 1 second for real-time acceptably accurate analyses of trace
577 metabolites in exhaled breath, and to the positive identification of unknown neutral trace gas
578 analytes at characteristic analyte ions m/z values above 100 and beyond. Lower limits of
579 sensitivity have been reported for specific trace compounds in air but not yet realised for
580 general use [11].

581
582 Thus, identification of isobaric and isomeric compounds is generally not possible, but the
583 incorporation of TOF-MS could help. The operation of SIFT-MS instruments and data
584 interpretation is not easy for technicians, scientists and health professionals that do not have
585 knowledge of mass spectrometry and ion chemistry. To alleviate these weaknesses offers a
586 real challenge to the future development of SIFT-MS-type devices.

587 Thus, there are obvious *opportunities* for instrumental development such as the improvement
588 of analytical sensitivity and the reductions in size and cost, but importantly retaining the
589 striking and unique features of real-time analyses and accurate quantification of trace
590 compounds. These developments are now in train in our Prague laboratory which, when
591 realised, will widen the exploitation of SIFT-MS in other areas of research and commerce
592 such as, for example, in the surgeries of general practitioners where wide screening by real-
593 time breath analysis could be carried out routinely and non-invasively for abnormal levels of
594 disease-related breath metabolites.

595
596 The *threats* that are evident to the wider use of SIFT-MS in medicine largely revolve around
597 the reluctance of clinicians to adopt breath analysis as an aid to clinical diagnoses and
598 therapeutic monitoring even though it has great potential as a non-invasive diagnostic; this is
599 de-motivating to research workers in this field. Their negative, often justified assessment is
600 partly due to the failure of research workers in breath analysis to convincingly articulate their
601 experimental work and to the premature reporting of inconsistent results that often defy
602 previous work without explanation. There is even the tendency to ignore the essential
603 requirements for biomarker identification and accurate quantification for the sake of
604 expediency and the urge by institutional management authorities for more publications
605 (“publish and be damned”). Additionally, the adoption of inadequate analytical methods that
606 fail to identify genuine biomarkers and the excessive reliance on statistics to assess unreliable
607 data is a major problem, as highlighted previously. Nevertheless, we believe that direct on-
608 line SIFT-MS analysis offers the best hope for the acceptance of breath analysis into medical
609 practice. It is perhaps significant that the wider growing use of SIFT-MS is in the less
610 stringent areas of food monitoring and ambient trace gas detection as alluded to previously.

611

612 **Summary remarks**

613 What are the essential points that can be extracted from the above “Perspective”? They are
614 that SIFT-MS is a unique and valuable addition to ambient trace gas analysis in that direct
615 on-line analysis of volatile compounds in ambient air and very humid exhaled breath can be
616 achieved. This offers a rapid, direct non-invasive analytical method to assist clinical
617 diagnosis and therapeutic monitoring that is not offered by breath sample collection and off-
618 line GC-MS analysis. SIFT-MS analysis is relatively straightforward for the analysis of
619 known trace compounds present at easily measurable concentrations. But when searching for
620 and accurately analysing less common trace gases or breath metabolites, it must be used with
621 aforethought with an eye on the underlying physics and chemistry in order to avoid serious

622 errors that would damn this analytical method in the eyes of clinicians. An important point to
623 stress is that the over reliance on statistical analysis when interpreting arrays of SIFT-MS
624 (and GC-MS) data can often lead to misleading and even false results and deductions, which
625 obviously is disastrous in medicine. Too little effort is given to the identification and accurate
626 quantification of single breath metabolites that can be used as meaningful diagnostic
627 biomarkers. Too much reliance is placed on patterns of several **volatile metabolites** that are
628 collectively labelled as biomarkers, which will never to be exploited by clinicians. The
629 strengths and weaknesses of SIFT-MS are made clear in this article, and the requirements for
630 instrumental improvement are spelled out that, if achieved, will remove the threats to the
631 extension and wider use of SIFT-MS in medicine and other areas.

632 **Future perspective**

633 A necessary development of SIFT-MS is the improvement of trace compound identification
634 and analytical sensitivity. This is partly envisaged by commencing development of new
635 method, SIFDT-MS, that includes a drift-tube reactor, and the inclusion of thermal
636 desorption elements for analyses of samples collected on sorbent tubes.

637
638 It is anticipated that small hand-held instruments will be developed involving optical
639 spectroscopy and solid state sensors to target individual biomarker molecules.

640
641 When further analyte ion resolution is needed to separate isobaric ions then the combination
642 of SIFT-MS with GC-MS will be further exploited to guarantee more certain compound
643 identification and accurate quantification of biomarkers that can be adopted in medicine.

644
645 Further efforts must be made to identify and quantify single breath biomarkers. When
646 compound “profiling is the only way forward then better understanding of statistical methods
647 for data interpretation need to be investigated.

648

649

Executive summary

650
651
652
653
654
655

- As the need for the analysis of more complex trace compounds arises, the challenges to SIFT-MS analyses grow and more detailed ion chemistry investigations are required, especially associated with the involvement of adduct ion formation. To obtain more certain compound identification, it is strongly advised to combine GC-MS and SIFT-MS analyses, especially when isobaric and isomeric compounds are involved.

656
657
658

- The analysis of trace gases (metabolites) in humid exhaled breath presents a serious analytical challenge. SIFT-MS provides the best route to direct, non-invasive real time analysis of single breath exhalations.

659
660

- Guidance as to the best approach to breath analysis and examples of the data that can be obtained by SIFT-MS are given as a guideline to the required quality.

661
662
663
664

- Reliance on statistical analyses to distinguish “normal breath” from “diseased breath” should be diminished with greater focus on the identification of single biomarkers of disease that are much more likely to be adopted as useful biomarkers of disease.

665
666
667

- SIFT-MS has been exploited to monitor volatile organic compounds from food and food products in real time and those released by mammalian and bacterial cell cultures *in vitro*.

668
669
670

- Strengths, weaknesses, opportunities and threats (SWOT analysis) in SIFT-MS is given, an appreciation of which will further establish it as a valuable method in the panoply of analytical methods being developed for gas analysis.

671

672

673 Bibliography

674 Papers of special note have been highlighted as:

675 * of interest

676 ** of considerable interest

677

678 1. Smith D, Španěl P: Pitfalls in the analysis of volatile breath biomarkers; suggested
679 solutions and SIFT-MS quantification of single metabolites. *J. Breath Res.* 9(2),
680 022001 (2015).

681 ** A perspective article discussing the difficulties and the proper approach to SIFT-MS
682 breath analysis

683 2. Smith D, Španěl P: Direct, rapid quantitative analyses of BVOCs using SIFT-MS and
684 PTR-MS obviating sample collection. *TrAC* 30(7), 945-959 (2011).

685 3. Španěl P, Smith D: Progress in SIFT-MS: Breath analysis and other applications.
686 *Mass Spectrom. Rev.* 30(2), 236-267 (2011).

687 ** A detailed overview of the SIFT-MS technique and the areas of application.

688 4. Smith D, Španěl P: Ambient analysis of trace compounds in gaseous media by SIFT-
689 MS. *Analyst* 136(10), 2009-2032 (2011).

690 5. Smith D, Španěl P: Selected ion flow tube mass spectrometry (SIFT-MS) for on-line
691 trace gas analysis. *Mass Spectrom. Rev.* 24(5), 661-700 (2005).

692 6. Španěl P, Dryahina K, Smith D: A general method for the calculation of absolute
693 trace gas concentrations in air and breath from selected ion flow tube mass
694 spectrometry data. *Int. J. Mass Spectrom.* 249, 230-239 (2006).

695 * A full description of the SIFT-MS analytical technique for absolute quantification.

696 7. Boshier PR, Cushnir JR, Mistry V *et al.*: On-line, real time monitoring of exhaled
697 trace gases by SIFT-MS in the perioperative setting: a feasibility study. *Analyst*
698 136(16), 3233-3237 (2011).

699 8. Smith D, Španěl P, Herbig J, Beauchamp J: Mass spectrometry for real-time
700 quantitative breath analysis. *J. Breath Res.* 8(2), 027101 (2014).

701 9. Španěl P, Smith D: Advances in On-line Absolute Trace Gas Analysis by SIFT-MS.
702 *Curr. Anal. Chem.* 9(4), 525-539 (2013).

703 10. Ross B: Sub-parts per billion detection of trace volatile chemicals in human breath
704 using selected ion flow tube mass spectrometry. *BMC Research Notes* 1(1), 41
705 (2008).

706 11. Prince BJ, Milligan DB, Mcewan MJ: Application of selected ion flow tube mass
707 spectrometry to real-time atmospheric monitoring. *Rapid Commun. Mass Spectrom.*
708 24(12), 1763-1769 (2010).

709 12. Chippendale TWE, Španěl P, Smith D, El Haj AJ: Counting cell number in situ by
710 quantification of dimethyl sulphide in culture headspace. *Analyst* 139(19), 4903-4907
711 (2014).

712 13. Smith D, Bloor R, George C, Pysanenko A, Španěl P: Release of toxic ammonia and
713 volatile organic compounds by heated cannabis and their relation to
714 tetrahydrocannabinol content. *Analytical Methods* 7(10), 4104-4110 (2015).

715 14. Sovova K, Wiggins T, Markar SR, Hanna GB: Quantification of phenol in urine
716 headspace using SIFT-MS and investigation of variability with respect to urinary
717 concentration. *Analytical Methods* 7(12), 5134-5141 (2015).

718 15. Xu Y, Barringer S: Comparison of tomatillo and tomato volatile compounds in the
719 headspace by selected ion flow tube mass spectrometry (SIFT-MS). *J. Food Sci.* 5,
720 268-273 (2013).

- 721 16. Langford VS, Milligan DB, Prince BJ, Mcewan MJ: Application of selected ion flow
722 tube mass spectrometry (SIFT-MS) to classifying coffee and parmesan cheese.
723 *Abstracts of Papers of the American Chemical Society* 247, 1 (2014).
- 724 17. Heynderickx PM, Španěl P, Van Langenhove H: Quantification of octanol-water
725 partition coefficients of several aldehydes in a bubble column using selected ion flow
726 tube mass spectrometry. *Fluid Phase Equilibria* 367, 22-28 (2014).
- 727 18. Shestivska V, Antonowicz SS, Dryahina K, Kubišta J, Smith D, Španěl P: Direct
728 detection and quantification of malondialdehyde vapour in humid air using selected
729 ion flow tube mass spectrometry supported by gas chromatography/mass
730 spectrometry. *Rapid Commun. Mass Spectrom.* 29(11), 1069-1079 (2015).
- 731 * First quantification of malondialdehyde in the gas phase.
- 732 19. Kumar S, Huang J, Abbassi-Ghadi N *et al.*: Mass Spectrometric Analysis of Exhaled
733 Breath for the Identification of Volatile Organic Compound Biomarkers in
734 Esophageal and Gastric Adenocarcinoma. *Annals of surgery* 262(6), 981-990 (2015).
- 735 20. Kumar S, Huang J, Abbassi-Ghadi N *et al.*: SIFT-MS analysis of exhaled breath for
736 volatile organic profiling of oesophago-gastric cancer. *Br. J. Surg.* 101, 17-18 (2014).
- 737 21. Dryahina K, Pospisilova V, Sovova K *et al.*: Exhaled breath concentrations of acetic
738 acid vapour in gastro-esophageal reflux disease. *J. Breath Res.* 8(3), 037109 (2014).
- 739 22. Kumar S, Huang JZ, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB: Selected Ion
740 Flow Tube Mass Spectrometry Analysis of Exhaled Breath for Volatile Organic
741 Compound Profiling of Esophago-Gastric Cancer. *Anal. Chem.* 85(12), 6121-6128
742 (2013).
- 743 23. Španěl P, Dryahina K, Vicherková P, Smith D: Increase of methanol in exhaled breath
744 quantified by SIFT-MS following aspartame ingestion. *J. Breath Res.* In press,
745 (2015).
- 746 24. Gilchrist F, Belcher J, Jones A *et al.*: Exhaled breath hydrogen cyanide as a marker of
747 early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. *The Lancet*
748 *Respiratory Medicine* Submitted, (2015).
- 749 25. Smith D, Španěl P: The SIFT and FALP techniques; applications to ionic and
750 electronic reactions studies and their evolution to the SIFT-MS and FA-MS analytical
751 methods. *Int. J. Mass Spectrom.* 377(0), 467-478 (2015).
- 752 * Historical development of laboratory techniques to study kinetics into analytical methods.
- 753 26. Smith D, Španěl P: SIFT-MS and FA-MS methods for ambient gas phase analysis:
754 developments and applications in the UK. *Analyst* 140(8), 2573-2591 (2015).
- 755 27. Davies SJ, Španěl P, Smith D: Breath analysis of ammonia, volatile organic
756 compounds and deuterated water vapor in chronic kidney disease and during dialysis.
757 *Bioanalysis* 6(6), 843-857 (2014).
- 758 28. Španěl P, Smith D: Account On the features, successes and challenges of selected ion
759 flow tube mass spectrometry. *Eur. J. Mass Spectrom.* 19(4), 225-246 (2013).
- 760 29. Smith D, Španěl P, Gilchrist FJ, Lenney W: Hydrogen cyanide, a volatile biomarker
761 of *Pseudomonas aeruginosa* infection. *J. Breath Res.* 7(4), 044001 (2013).
- 762 * A summary of a decade of research that establishes HCN as a biomarker of *Pseudomonas*
763 *aeruginosa* infection.
- 764 30. Sovová K, Dryahina K, Španěl P: Selected ion flow tube (SIFT) studies of the
765 reactions of H_3O^+ , NO^+ and O_2^{++} with six volatile phytogetic esters. *Int. J. Mass*
766 *Spectrom.* 300(1), 31-38 (2011).
- 767 31. Smith D, Sovová K, Španěl P: A selected ion flow tube study of the reactions of
768 H_3O^+ , NO^+ and O_2^+ with seven isomers of hexanol in support of SIFT-MS. *Int. J.*
769 *Mass Spectrom.* 319, 25-30 (2012).

- 770 32. Michalčíková RB, Španěl P: A selected ion flow tube study of the ion molecule
771 association reactions of protonated (MH^+), nitrosonated (MNO^+) and dehydroxidated
772 ($M-OH^{(+)}$) carboxylic acids (M) with H_2O . *Int. J. Mass Spectrom.* 368, 15-22 (2014).
- 773 33. Smith D, Chippendale TWE, Španěl P: Reactions of the selected ion flow tube mass
774 spectrometry reagent ions H_3O^+ and NO^+ with a series of volatile aldehydes of
775 biogenic significance. *Rapid Commun. Mass Spectrom.* 28(17), 1917-1928 (2014).
- 776 34. Smith D, Pysanenko A, Španěl P: Ionic diffusion and mass discrimination effects in
777 the new generation of short flow tube SIFT-MS instruments. *Int. J. Mass Spectrom.*
778 281(1-2), 15-23 (2009).
- 779 * A detailed description of the construction and analytical performance of the *Profile 3*
780 SIFT-MS instrument.
- 781 35. Španěl P, Smith D: Influence of water vapour on selected ion flow tube mass
782 spectrometric analyses of trace gases in humid air and breath. *Rapid Commun. Mass*
783 *Spectrom.* 14(20), 1898-1906 (2000).
- 784 36. Španěl P, Smith D: Influence of weakly bound adduct ions on breath trace gas
785 analysis by selected ion flow tube mass spectrometry (SIFT-MS). *Int. J. Mass*
786 *Spectrom.* 280(1-3), 128-135 (2009).
- 787 37. Pysanenko A, Španěl P, Smith D: A study of sulfur-containing compounds in mouth-
788 and nose-exhaled breath and in the oral cavity using selected ion flow tube mass
789 spectrometry. *J. Breath Res.* 2(4), 046004 (2008).
- 790 * Significance of nose breath sampling to reduce the oral contribution to mouth exhaled
791 metabolite concentrations.
- 792 38. Langford VS, Gray JDC, Maclagan RGA, Milligan DB, Mcewan MJ: Real-time
793 measurements of nitrosamines in air. *Int. J. Mass Spectrom.* 377, 490-495 (2015).
- 794 39. Zhan XF, Duan JN, Duan YX: Recent developments of proton-transfer reaction mass
795 spectrometry (PTR-MS) and its applications in medical research. *Mass Spectrom.*
796 *Rev.* 32(2), 143-165 (2013).
- 797 40. Joo E, Dewulf J, Demarcke M *et al.*: Quantification of interferences in PTR-MS
798 measurements of monoterpene emissions from *Fagus sylvatica* L. using simultaneous
799 TD-GC-MS measurements. *Int. J. Mass Spectrom.* 291(1-2), 90-95 (2010).
- 800 41. Španěl P, Smith D: On-line measurement of the absolute humidity of air, breath and
801 liquid headspace samples by selected ion flow tube mass spectrometry. *Rapid*
802 *Commun. Mass Spectrom.* 15(8), 563-569 (2001).
- 803 42. Heijkenskjold-Rentzhog C, Alving K, Kalm-Stephens P, Lundberg JO, Nordvall L,
804 Malinowski A: The fraction of NO in exhaled air and estimates of alveolar NO in
805 adolescents with asthma: Methodological aspects. *Pediatr. Pulmonol.* 47(10), 941-949
806 (2012).
- 807 43. Sachs-Olsen C, Carlsen KCL, Mowinckel P *et al.*: Diagnostic value of exhaled nitric
808 oxide in childhood asthma and allergy. *Pediatr. Allergy Immunol.* 21(1), E213-E221
809 (2010).
- 810 44. Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ: Further characterization of a C-
811 13-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients
812 on tamoxifen therapy. *J. Breath Res.* 9(2), (2015).
- 813 45. Modak AS: An Update on C-13-Breath Tests: The Transition to Acceptability into
814 Clinical Practice. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and*
815 *Medicine*, 245-262 (2013).
- 816 46. Amelynck C, Mees B, Schoon N, Bultinck P: FA-SIFT study of the reactions of H_3O^+
817 (H_2O)_n (n=0, 1, 2), NO^+ and O_2^+ with the terpenoid aldehydes citral, citronellal and
818 myrtenal and their alcohol analogues. *Int. J. Mass Spectrom.* 379, 52-59 (2015).

- 819 47. Amelynck C, Schoon N, Dhooghe F: SIFT Ion Chemistry Studies Underpinning the
820 Measurement of Volatile Organic Compound Emissions by Vegetation. *Curr. Anal.*
821 *Chem.* 9(4), 540-549 (2013).
- 822 48. Smith D, Chippendale TWE, Španěl P: Minimising the Effects of Isobaric Product
823 Ions in SIFT-MS Quantification of Acetaldehyde, Dimethyl Sulphide and Carbon
824 Dioxide. *Curr. Anal. Chem.* 9(4), 550-557 (2013).
- 825 49. Alsabbagh MEY, Chami AT, Gurshawn S *et al.*: Exhaled Breath Analysis Reveals
826 New Biomarkers to Diagnose Advanced Fibrosis in Patients with Chronic Liver
827 Disease. *Hepatology* 60, 417a-418a (2014).
- 828 50. Eng K, Alkhouri N, Cikach F *et al.*: Analysis of breath volatile organic compounds in
829 children with chronic liver disease compared to healthy controls. *J. Breath Res.* 9(2),
830 (2015).
- 831 51. Kurada S, Grove D, Alkhouri N *et al.*: A Specific Breath Metabolome Signature
832 Identifies Patients With Inflammatory Bowel Diseases. *Am. J. Gastroenterol.* 110,
833 S783-S783 (2015).
- 834 52. Samara MA, Tang WHW, Cikach F *et al.*: Single Exhaled Breath Metabolomic
835 Analysis Identifies Unique Breathprint in Patients With Acute Decompensated Heart
836 Failure. *Journal of the American College of Cardiology* 61(13), 1463-1464 (2013).
- 837 53. Patel N, Alkhouri N, Eng K *et al.*: Metabolomic analysis of breath volatile organic
838 compounds reveals unique breathprints in children with inflammatory bowel disease:
839 a pilot study. *Aliment. Pharmacol. Ther.* 40(5), 498-507 (2014).
- 840 * A very good example of SIFT-MS breath analysis revealing a group of volatile metabolites
841 as biomarkers of a disease
- 842 54. Alkhouri N, Eng K, Cikach F *et al.*: Breathprints of childhood obesity: changes in
843 volatile organic compounds in obese children compared with lean controls. *Pediatric*
844 *Obesity* 10(1), 23-29 (2015).
- 845 55. Okwu V, Matloob A, Grove D *et al.*: Volatile Organic Compounds in the Exhaled
846 Breath as Biomarkers of Nonalcoholic Steatohepatitis in Obese Children. *Am. J.*
847 *Gastroenterol.* 109, S145-S145 (2014).
- 848 56. Zeft A, Costanzo D, Alkhouri N *et al.*: Metabolomic Analysis of Breath Volatile
849 Organic Compounds Reveals Unique Breathprints in Children With Juvenile
850 Idiopathic Arthritis. *Arthritis & Rheumatology* 66, S159-S159 (2014).
- 851 57. Kurada S, Grove D, Singh A *et al.*: The Breath Metabolome in Patients With Pouch
852 Disorders. *Am. J. Gastroenterol.* 110, S797-S797 (2015).
- 853 58. Kumar S, Huang J, Hanna GB: SIFT-MS analysis of headspace vapour from gastric
854 content for the diagnosis of gastro-oesophageal cancer. *Br. J. Surg.* 100, 4-4 (2013).
- 855 * A first example of SIFT-MS analysis of volatile compounds emitted by liquid gastric
856 content
- 857 59. Huang JZ, Kumar S, Boshier PR, Wakefield S, Cushnir JR, Hanna GB: Breath
858 Analysis Using SIFT-MS to Assess Metabolic Status in Patients After Gastro-
859 oesophageal Cancer Surgery- a Pilot Study. *Curr. Anal. Chem.* 9(4), 584-592 (2013).
- 860 60. Huang JZ, Kumar S, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB: Selected Ion
861 Flow Tube Mass Spectrometry Analysis of Volatile Metabolites in Urine Headspace
862 for the Profiling of Gastro-Esophageal Cancer. *Anal. Chem.* 85(6), 3409-3416 (2013).
- 863 61. Kumar S, Huang JZ, Cushnir JR, Španěl P, Smith D, Hanna GB: Selected Ion Flow
864 Tube-MS Analysis of Headspace Vapor from Gastric Content for the Diagnosis of
865 Gastro-Esophageal Cancer. *Anal. Chem.* 84(21), 9550-9557 (2012).

- 866 62. Huang J, Kumar S, Hanna GB: Investigation of C3-C10 aldehydes in the exhaled
867 breath of healthy subjects using selected ion flow tube-mass spectrometry (SIFT-MS).
868 *J Breath Res* 8(3), 037104 (2014).
- 869 63. Hicks LC, Huang J, Kumar S *et al.*: Analysis of Exhaled Breath Volatile Organic
870 Compounds in Inflammatory Bowel Disease: A Pilot Study. *J. Crohns Colitis* 9(9),
871 731-737 (2015).
- 872 64. Smith D, Turner C, Španěl P: Volatile metabolites in the exhaled breath of healthy
873 volunteers: their levels and distributions. *J. Breath Res.* 1(1), 014004 (2007).
- 874 * A review of the concentrations of several metabolites in the exhaled breath of the normal
875 population.
- 876 65. Turner C, Španěl P, Smith D: A longitudinal study of ammonia, acetone and propanol
877 in the exhaled breath of 30 subjects using selected ion flow tube mass spectrometry,
878 SIFT-MS. *Physiol. Meas.* 27(4), 321-337 (2006).
- 879 66. Turner C, Španěl P, Smith D: A longitudinal study of breath isoprene in healthy
880 volunteers using selected ion flow tube mass spectrometry (SIFT-MS). *Physiol. Meas.*
881 27(1), 13-22 (2006).
- 882 67. Turner C, Španěl P, Smith D: A longitudinal study of ethanol and acetaldehyde in the
883 exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry.
884 *Rapid Commun. Mass Spectrom.* 20(1), 61-68 (2006).
- 885 68. Turner C, Španěl P, Smith D: A longitudinal study of methanol in the exhaled breath
886 of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS.
887 *Physiol. Meas.* 27(7), 637-648 (2006).
- 888 69. Turner C, Walton C, Hoashi S, Evans M: Breath acetone concentration decreases with
889 blood glucose concentration in type I diabetes mellitus patients during hypoglycaemic
890 clamps. *J. Breath Res.* 3(4), (2009).
- 891 70. Cauchi M, Fowler DP, Walton C *et al.*: Comparison of GC-MS, HPLC-MS and SIFT-
892 MS in conjunction with multivariate classification for the diagnosis of Crohn's disease
893 in urine. *Analytical Methods* 7(19), 8379-8385 (2015).
- 894 71. Walton C, Patel M, Pitts D *et al.*: The use of a portable breath analysis device in
895 monitoring type 1 diabetes patients in a hypoglycaemic clamp: validation with SIFT-
896 MS data. *J. Breath Res.* 8(3), (2014).
- 897 72. Batty CA, Cauchi M, Lourenco C, Hunter JO, Turner C: Use of the Analysis of the
898 Volatile Faecal Metabolome in Screening for Colorectal Cancer. *Plos One* 10(6),
899 (2015).
- 900 * An example of a SIFT-MS study revealing the concentrations of single compounds as breath
901 biomarkers.
- 902 73. Hopes K, Cauchi M, Walton C, Macqueen H, Wassif W, Turner C: A novel method
903 for the analysis of clinical biomarkers to investigate the effect of diet on health in a rat
904 model. *Analyst* 140(9), 3028-3038 (2015).
- 905 74. Hryniuk A, Ross BM: Detection of acetone and isoprene in human breath using a
906 combination of thermal desorption and selected ion flow tube mass spectrometry. *Int.*
907 *J. Mass Spectrom.* 285(1-2), 26-30 (2009).
- 908 75. Ross BM, Vermeulen N: The combined use of thermal desorption and selected ion
909 flow tube mass spectrometry for the quantification of xylene and toluene in air. *Rapid*
910 *Commun. Mass Spectrom.* 21(22), 3608-3612 (2007).
- 911 * The first use of ATD and SIFT-MS in combination for trace gas analysis.
- 912 76. Wondimu T, Wang R, Ross BM: A Comparison of Moisture Removing Strategies for
913 Breath Samples Spiked with Trace Concentrations of Hydrogen Sulphide. *Curr. Anal.*
914 *Chem.* 9(2), 312-318 (2013).

- 915 77. Wondimu T, Wang R, Ross B: Hydrogen sulphide in human nasal air quantified using
916 thermal desorption and selected ion flow tube mass spectrometry. *J. Breath Res.* 8(3),
917 8 (2014).
- 918 78. Ross BM, Puukila S, Malik I *et al.*: The Use of SIFT-MS to Investigate Headspace
919 Aldehydes as Markers of Lipid Peroxidation. *Curr. Anal. Chem.* 9(4), 600-613
920 (2013).
- 921 79. Ross BM, Babay S, Malik I: Brain and Liver Headspace Aldehyde Concentration
922 Following Dietary Supplementation with n-3 Polyunsaturated Fatty Acids. *Lipids*
923 50(11), 1123-1131 (2015).
- 924 80. Amadei G, Ross BM: Quantification of character-impacting compounds in *Ocimum*
925 *basilicum* and 'Pesto alla Genovese' with selected ion flow tube mass spectrometry.
926 *Rapid Commun. Mass Spectrom.* 26(3), 219-225 (2012).
- 927 81. Malek L, Gibson A, Dekker RFH, Ross BM: Sift-MS Analysis of Methanol
928 Chemically and Biologically Generated from Lignin. *J-for-Journal of Science &*
929 *Technology for Forest Products and Processes* 4(2), 6-10 (2014).
- 930 82. Gilchrist FJ, Bright-Thomas RJ, Jones AM *et al.*: Hydrogen cyanide concentrations in
931 the breath of adult cystic fibrosis patients with and without *Pseudomonas aeruginosa*
932 infection. *J. Breath Res.* 7(2), 026010 (2013).
- 933 83. Gilchrist FJ, Sims H, Alcock A *et al.*: Quantification of hydrogen cyanide and 2-
934 aminoacetophenone in the headspace of *Pseudomonas aeruginosa* cultured under
935 biofilm and planktonic conditions. *Analytical Methods* 4(11), 3661-3665 (2012).
- 936 84. Gilchrist FJ, Razavi C, Webb AK *et al.*: An investigation of suitable bag materials for
937 the collection and storage of breath samples containing hydrogen cyanide. *J. Breath*
938 *Res.* 6(3), 036004 (2012).
- 939 85. Gilchrist FJ, Alcock A, Belcher J *et al.*: Variation in hydrogen cyanide production
940 between different strains of *Pseudomonas aeruginosa*. *European Respiratory Journal*
941 38(2), 409-414 (2011).
- 942 86. Enderby B, Smith D, Carroll W, Lenney W: Hydrogen Cyanide as a Biomarker for
943 *Pseudomonas Aeruginosa* in the Breath of Children With Cystic Fibrosis. *Pediatr.*
944 *Pulmonol.* 44(2), 142-147 (2009).
- 945 87. Shestivska V, Španěl P, Dryahina K *et al.*: Variability in the concentrations of volatile
946 metabolites emitted by genotypically different strains of *Pseudomonas aeruginosa*. *J.*
947 *Appl. Microbiol.* 113(3), 701-713 (2012).
- 948 * SIFT-MS and GC-MS analyses of volatile metabolites from 36 genetically different strains
949 88. Shestivska V, Nemeč A, Drevinek P, Sovová K, Dryahina K, Španěl P: Quantification
950 of methyl thiocyanate in the headspace of *Pseudomonas aeruginosa* cultures and in the
951 breath of cystic fibrosis patients by selected ion flow tube mass spectrometry. *Rapid*
952 *Commun. Mass Spectrom.* 25(17), 2459-2467 (2011).
- 953 89. Dryahina K, Španěl P, Pospisilova V *et al.*: Quantification of pentane in exhaled
954 breath, a potential biomarker of bowel disease, using selected ion flow tube mass
955 spectrometry. *Rapid Commun. Mass Spectrom.* 27(17), 1983-1992 (2013).
- 956 90. Hrdlicka L, Dryahina K, Španěl P *et al.*: Noninvasive Quantification of Volatile
957 Metabolites in Breath: A Potential Indicator of Inflammatory Bowel Diseases
958 Activity. *Gastroenterology* 142(5), S784-S784 (2012).
- 959 91. Dryahina K, Smith D, Španěl P: Quantification of methane in humid air and exhaled
960 breath using selected ion flow tube mass spectrometry. *Rapid Commun. Mass*
961 *Spectrom.* 24(9), 1296-1304 (2010).
- 962 92. Szabo A, Ruzsanyi V, Unterkofler K *et al.*: Exhaled methane concentration profiles
963 during exercise on an ergometer. *J. Breath Res.* 9(1), 016009 (2015).

- 964 93. Spesyvyi A, Španěl P: Determination of residence times of ions in a resistive glass
965 selected ion flow-drift tube using the Hadamard transformation. *Rapid Commun.*
966 *Mass Spectrom.* 29(17), 1563-1570 (2015).
- 967 94. Spesyvyi A, Smith D, Španěl P: Selected Ion Flow-Drift Tube Mass Spectrometry:
968 Quantification of Volatile Compounds in Air and Breath. *Anal. Chem.* 87(24), 12151-
969 12160 (2015).
- 970 * The first description of the SIFDT-MS analytical method
- 971 95. Dummer J, Storer M, Sturney S *et al.*: Quantification of hydrogen cyanide (HCN) in
972 breath using selected ion flow tube mass spectrometry-HCN is not a biomarker of
973 *Pseudomonas* in chronic suppurative lung disease. *J. Breath Res.* 7(1), 017105 (2013).
- 974 96. Chambers ST, Scott-Thomas A, Epton M: Developments in novel breath tests for
975 bacterial and fungal pulmonary infection. *Current Opinion in Pulmonary Medicine*
976 18(3), 228-232 (2012).
- 977 97. Storer M, Dummer J, Lunt H *et al.*: Measurement of breath acetone concentrations by
978 selected ion flow tube mass spectrometry in type 2 Diabetes. *J. Breath Res.* 5(4),
979 046011 (2011).
- 980 98. Sturney SC, Storer MK, Shaw GM, Shaw DE, Epton MJ: Off-line breath acetone
981 analysis in critical illness. *J. Breath Res.* 7(3), 9 (2013).
- 982 99. Storer M, Curry K, Squire M, Kingham S, Epton M: Breath testing and personal
983 exposure-SIFT-MS detection of breath acetonitrile for exposure monitoring. *J. Breath*
984 *Res.* 9(3), (2015).
- 985 * Demonstrating the use of SIFT-MS analysis in exposure studies
- 986 100. Storer M, Salmond J, Dirks KN, Kingham S, Epton M: Mobile selected ion flow tube
987 mass spectrometry (SIFT-MS) devices and their use for pollution exposure
988 monitoring in breath and ambient air-pilot study. *J. Breath Res.* 8(3), 037106 (2014).
- 989 101. Sumonsiri N, A Barringer S: Application of SIFT-MS in Monitoring Volatile
990 Compounds in Fruits and Vegetables. *Curr. Anal. Chem.* 9(4), 631-641 (2013).
- 991 102. Akpolat H, Barringer SA: The Effect of pH and Temperature on Cabbage Volatiles
992 During Storage. *Journal of Food Science* 80(8), S1878-S1884 (2015).
- 993 103. Smith AL, Perry JJ, Marshall JA, Yousef AE, Barringer SA: Oven, Microwave, and
994 Combination Roasting of Peanuts: Comparison of Inactivation of *Salmonella*
995 Surrogate *Enterococcus faecium*, Color, Volatiles, Flavor, and Lipid Oxidation.
996 *Journal of Food Science* 79(8), S1584-S1594 (2014).
- 997 104. Smith AL, Barringer SA: Color and Volatile Analysis of Peanuts Roasted Using Oven
998 and Microwave Technologies. *Journal of Food Science* 79(10), C1895-C1906 (2014).
- 999 105. Flores M, Olivares A, Dryahina K, Španěl P: Real Time Detection of Aroma
1000 Compounds in Meat and Meat Products by SIFT-MS and Comparison to
1001 Conventional Techniques (SPME-GC-MS). *Curr. Anal. Chem.* 9(4), 622-630 (2013).
- 1002 106. Olivares A, Dryahina K, Španěl P, Flores M: Rapid detection of lipid oxidation in
1003 beef muscle packed under modified atmosphere by measuring volatile organic
1004 compounds using SIFT-MS. *Food Chem.* 135(3), 1801-1808 (2012).
- 1005 107. Munch R, Barringer SA: Deodorization of Garlic Breath Volatiles by Food and Food
1006 Components. *Journal of Food Science* 79(4), C526-C533 (2014).
- 1007 * Demonstrating the influence of odorous foods on breath trace compounds.
- 1008 108. Smith D, Wang TS, Sule-Suso J, Španěl P, El Haj A: Quantification of acetaldehyde
1009 released by lung cancer cells in vitro using selected ion flow tube mass spectrometry.
1010 *Rapid Commun. Mass Spectrom.* 17(8), 845-850 (2003).

- 1011 109. Wang TS, Smith D, Španěl P: Selected ion flow tube, SIFT, studies of the reactions of
1012 H_3O^+ , NO^+ and O_2^+ with compounds released by *Pseudomonas* and related bacteria.
1013 *Int. J. Mass Spectrom.* 233(1-3), 245-251 (2004).
- 1014 110. Allardyce RA, Hill AL, Murdoch DR: The rapid evaluation of bacterial growth and
1015 antibiotic susceptibility in blood cultures by selected ion flow tube mass spectrometry.
1016 *Diagn. Microbiol. Infect. Dis.* 55(4), 255-261 (2006).
- 1017 111. Allardyce RA, Langford VS, Hill AL, Murdoch DR: Detection of volatile metabolites
1018 produced by bacterial growth in blood culture media by selected ion flow tube mass
1019 spectrometry (SIFT-MS). *J. Microbiol. Methods* 65(2), 361-365 (2006).
- 1020 112. Scotter JM, Allardyce RA, Langford V, Hill A, Murdoch DR: The rapid evaluation of
1021 bacterial growth in blood cultures by selected ion flow tube-mass spectrometry (SIFT-
1022 MS) and comparison with the BacT/ALERT automated blood culture system. *J.*
1023 *Microbiol. Methods* 65(3), 628-631 (2006).
- 1024 113. Chingin K, Liang JC, Chen HW: Direct analysis of in vitro grown microorganisms
1025 and mammalian cells by ambient mass spectrometry. *Rsc Adv* 4(11), 5768-5781
1026 (2014).
- 1027 114. Španěl P, Smith D: *Recent SIFT-MS Studies of Volatile Compounds in Physiology,*
1028 *Medicine and Cell Biology.* In: *Volatile Biomarkers: Non-Invasive Diagnosis in*
1029 *Physiology and Medicine,* Amann A, Smith D (Ed.^(Eds). Elsevier, Boston 49-76
1030 (2013).
- 1031 115. Rutter AV, Chippendale TWE, Yang Y, Španěl P, Smith D, Sule-Suso J:
1032 Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model.
1033 *Analyst* 138(1), 91-95 (2013).
- 1034 116. Chippendale TWE, Hu B, El Haj AJ, Smith D: A study of enzymatic activity in cell
1035 cultures via the analysis of volatile biomarkers. *Analyst* 137(20), 4677-4685 (2012).
- 1036 117. Sule-Suso J, Pysanenko A, Španěl P, Smith D: Quantification of acetaldehyde and
1037 carbon dioxide in the headspace of malignant and non-malignant lung cells in vitro by
1038 SIFT-MS. *Analyst* 134(12), 2419-2425 (2009).
- 1039 118. Chippendale TWE, Španěl P, Smith D: Time-resolved selected ion flow tube mass
1040 spectrometric quantification of the volatile compounds generated by *E. coli* JM109
1041 cultured in two different media. *Rapid Commun. Mass Spectrom.* 25(15), 2163-2172
1042 (2011).
- 1043 * The first real time analysis of dynamic changes in volatile emissions from bacterial
1044 cultures.
- 1045 119. Sovova K, Cepl J, Markos A, Španěl P: Real time monitoring of population dynamics
1046 in concurrent bacterial growth using SIFT-MS quantification of volatile metabolites.
1047 *Analyst* 138(17), 4795-4801 (2013).

1048